We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Pfizer Wins Viagra Patent Case Against Teva

By LabMedica International staff writers
Posted on 19 Sep 2011
Teva (Petah Tikva, Israel) will have to wait eight more years before it can market a generic version of Viagra (sildenafil) in the United States.

The generic pharmaceutical giant has been trying to topple a method-of-use patent for the Pfizer (New York, NY, USA) erectile dysfunction (ED) drug that expires in October 2019, but the US District Court for the Eastern District of Virginia has decided that this should remain in force. More...
The patent challenge was launched on the grounds that Pfizer had double-patented Viagra in the USA --one expiring in March 2012 to treat heart-related issues and the second in 2019--and that the second use patent was invalid; it also argued that Pfizer withheld information from the US Patent and Trademark Office. Those assertions were dismissed by the judge in the case.

Pfizer reported Viagra sales of US$495 million in the second quarter of 2011, a rise of 1%, and is Pfizer's sixth best-selling brand. Around the world, however, the product has already started to lose patent protection in some markets (notably Brazil in June 2010), with more to come by the end of 2012. The reaffirmation of its US patent position is therefore a big boost for the franchise, since more than 50% of Viagra's sales are made in the USA, accounting for $1 billion a year in turnover.

“We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction,” said Amy Schulman, executive vice president and general counsel for Pfizer in a press release issued yesterday. “Protecting the intellectual property rights of our innovative core is critical, and Friday's court decision acknowledges Teva's clear violation of our patent rights.”

The decision is also good news for Eli Lilly (Indianapolis, IN, USA), the manufacturer of Cialis (tadalafil), and Bayer (Leverkusen, Germany), who makes Levitra (vardenafil), two other ED drugs whose sales would sharply decline with the introduction of a generic replacement.

Sildenafil citrate, sold as Viagra, is a drug used to treat ED and pulmonary arterial hypertension (PAH). It acts by inhibiting cGMP-specific phosphodiesterase type 5, an enzyme that delays degradation of cGMP. This results in increased levels of cGMP, leading to smooth muscle relaxation (vasodilation) of the intimal cushions of the helicine arteries. This smooth muscle relaxation leads to vasodilation and increased inflow of blood into the spongy tissue of the penis, causing an erection.

Related Links:

Teva
Pfizer
Eli Lilly



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.